Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Apellis Pharmaceuticals, Inc. is not a good value stock. Apellis Pharmaceuticals, Inc. is not a good growth stock. Apellis Pharmaceuticals, Inc. is not very popular among insiders. Apellis Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel th...
APLS Fundamental Data by TradingView

News

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Brokerages
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Zolmax Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are currently covering the firm, Marketbeat Ratings...\n more…

Bank of New York Mellon Corp Purchases 22,273 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Bank of New York Mellon Corp Purchases 22,273 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Ticker Report Bank of New York Mellon Corp boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 6.9% during the second quarter, according to the company in its most recent filing...\n more…

Candriam S.C.A. Lowers Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Candriam S.C.A. Lowers Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Ticker Report Candriam S.C.A. reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 7.2% in the 2nd quarter, according to its most recent disclosure with the Securities...\n more…

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 4.2%
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 4.2%

Zolmax Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was up 4.2% on Friday . The stock traded as high as $41.00 and last traded at $40.94. Approximately 42,345 shares changed hands during...\n more…

Stock Traders Purchase High Volume of Call Options on Apellis Pharmaceuticals (NASDAQ:APLS)
Stock Traders Purchase High Volume of Call Options on Apellis Pharmaceuticals (NASDAQ:APLS)

Zolmax Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the target of unusually large options trading activity on Friday. Investors bought 5,604 call options on the stock. This represents...\n more…

Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)
Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)

Ticker Report Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock investors bought 5,604 call options on the company. This is...\n more…